{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:12:47Z","timestamp":1776730367612,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control","award":["2011SKLID103"],"award-info":[{"award-number":["2011SKLID103"]}]},{"name":"National High Technology Research Program of China","award":["2012AA02A404"],"award-info":[{"award-number":["2012AA02A404"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.antiviral.2016.01.014","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T07:30:34Z","timestamp":1453707034000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice"],"prefix":"10.1016","volume":"128","author":[{"given":"Li-Li","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Qian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Bai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.01.014_bib1","doi-asserted-by":"crossref","first-page":"e78289","DOI":"10.1371\/journal.pone.0078289","article-title":"A\u00a0phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants","volume":"8","author":"Afolabi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2016.01.014_bib2","doi-asserted-by":"crossref","first-page":"P259","DOI":"10.1186\/1742-4690-9-S2-P259","article-title":"Recombinant DNA\/MVA\/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1","volume":"9","author":"Ahmed","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2016.01.014_bib3","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1128\/JVI.02443-08","volume":"83","author":"Bellone","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.vaccine.2005.08.041","article-title":"Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers","volume":"24","author":"Cebere","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2016.01.014_bib5","first-page":"117","article-title":"Human papillomavirus and oral cancer: a primer for dental public health professionals","volume":"32","author":"Chattopadhyay","year":"2015","journal-title":"Community Dent. Health"},{"key":"10.1016\/j.antiviral.2016.01.014_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/viro.1998.9372","article-title":"L1-specific protection from tumor challenge elicited by HPV16 virus-like particles","volume":"250","author":"De Bruijn","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.01.014_bib7","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.lpm.2014.10.001","article-title":"HPV in genital cancers (at the exception of cervical cancer) and anal cancers","volume":"43","author":"de Sanjose","year":"2014","journal-title":"Presse Med."},{"key":"10.1016\/j.antiviral.2016.01.014_bib8","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1128\/JVI.73.11.9063-9071.1999","article-title":"Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes","volume":"73","author":"Dupuy","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib9","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/171.4.1026","article-title":"Human papillomavirus infection is transient in young women: a population-based cohort study","volume":"171","author":"Evander","year":"1995","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.01.014_bib10","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1128\/JVI.68.9.5698-5705.1994","article-title":"The ability of human papillomavirus E6 proteins to target p53 for degradation in\u00a0vivo correlates with their ability to abrogate actinomycin D-induced growth arrest","volume":"68","author":"Foster","year":"1994","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib11","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0140-6736(04)16194-1","article-title":"A\u00a0causal role for human papillomavirus in head and neck cancer","volume":"363","author":"Gillison","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.01.014_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.antiviral.2016.01.014_bib13","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.01.014_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hed.23850","article-title":"HPV-related oropharyngeal cancer: risk factors for treatment failure in patients managed with primary transoral robotic surgery","volume":"38","author":"Kaczmar","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.antiviral.2016.01.014_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/srep01443","article-title":"Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1","volume":"3","author":"Lambe","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2016.01.014_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/156652307782151498","article-title":"Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions","volume":"7","author":"Lowenstein","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.antiviral.2016.01.014_bib17","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralblatt fur Bakteriol. Parasitenkd. Infekt. Hyg. Erste Abt. Orig. Reihe Hyg. Betriebshygiene Praventive Med."},{"key":"10.1016\/j.antiviral.2016.01.014_bib18","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors","volume":"81","author":"McCoy","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib19","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/j.1460-2075.1989.tb08594.x","article-title":"Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product","volume":"8","author":"Munger","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2016.01.014_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.oraloncology.2014.10.005","article-title":"The role of surgery for HPV-associated head and neck cancer","volume":"51","author":"Mydlarz","year":"2015","journal-title":"Oral Oncol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib21","first-page":"326","article-title":"Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules","volume":"54","author":"Nemeckova","year":"2007","journal-title":"Neoplasma"},{"key":"10.1016\/j.antiviral.2016.01.014_bib22","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1128\/JVI.77.8.4635-4645.2003","article-title":"Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL\/6 mice","volume":"77","author":"Ohlschlager","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2003.11.008","article-title":"CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses","volume":"9","author":"Reyes-Sandoval","year":"2004","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.antiviral.2016.01.014_bib24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of HPV intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.antiviral.2016.01.014_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.01.014_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2407-12-398","article-title":"HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues","volume":"12","author":"Stanley","year":"2012","journal-title":"BMC cancer"},{"key":"10.1016\/j.antiviral.2016.01.014_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0046-8177(92)90232-R","article-title":"Human papillomavirus type 16 and 18 gene expression in cervical neoplasias","volume":"23","author":"Stoler","year":"1992","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib28","first-page":"347","article-title":"Poxvirus bioinformatics","volume":"269","author":"Upton","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2016.01.014_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.antiviral.2016.01.014_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.antiviral.2016.01.014_bib31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1159\/000325229","article-title":"Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions","volume":"54","author":"Xiao","year":"2010","journal-title":"Acta Cytol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T09:54:25Z","timestamp":1600077265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216300183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"alternative-id":["S0166354216300183"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}